Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme

  1. Ruilope, L.M.
  2. Redón, J.
  3. Schmieder, R.
Journal:
Vascular Health and Risk Management

ISSN: 1176-6344

Year of publication: 2007

Volume: 3

Issue: 1

Pages: 1-9

Type: Review

GOOGLE SCHOLAR
Data source: Scopus